問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Linkou Chang Gung Medical Foundation

  • 0

    Total Beds

  • 0

    Total Doctors

  • 244New Taipei CityLinkou

Recruiting Trial

917Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

2322Cases

2025-10-01 - 2027-07-31

Phase II

Active
Integrating precision imaging technologies for rectal cancer patients receiving pre-treatment radiochemotherapy: hyperpolarized carbon-13 magnetic resonance imaging, metabolomics, and radiomics.

  • Condition/Disease

    rectal cancer

  • Test Drug

    Hyperpolarized [1-13C]Pyruvate

Participate Sites
1Sites

Recruiting1Sites

2025-10-01 - 2031-04-30

Phase III

Active
TRITON-PN: A phase 3, global, randomized, open-label trial evaluating the efficacy and safety of nucresiran in patients with hereditary transthyretin transporter amyloid polyneuropathy (hATTR-PN).

  • Condition/Disease

    Patients with hereditary transthyretin transporter amyloid polyneuropathy (hATTR-PN)

  • Test Drug

    Nucresiran (ALN-TTRSC04) vutrisiran (ALN-TTRSC02)

Participate Sites
3Sites

Recruiting3Sites

2025-02-07 - 2032-12-31

Phase I/II

Active
A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma

  • Test Drug

    凍晶注射劑 注射劑 注射劑 注射劑 注射劑 注射劑

Participate Sites
8Sites

Recruiting8Sites

2025-02-11 - 2038-02-19

Phase III

Active
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)

  • Condition/Disease

    Breast Cancer

  • Test Drug

    錠劑 錠劑 膠囊劑 錠劑 錠劑 錠劑

Participate Sites
8Sites

Recruiting8Sites

2025-02-01 - 2033-12-31

Phase II

Completed
A Phase 2, Umbrella Study to Evaluate the Safety, Tolerability, and Clinical Activity of Investigational Agents for Newly Diagnosed, High-Risk, Early-Stage Triple-Negative Breast Cancer

  • Condition/Disease

    Early Triple Negative Breast Cancer

  • Test Drug

    注射劑 注射劑

Participate Sites
3Sites

Recruiting3Sites

2025-11-01 - 2029-05-31

Phase III

Active
An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

  • Condition/Disease

    Chronic Kidney Disease

  • Test Drug

    Tablets Tablets Granules for suspension Granules for suspension

Participate Sites
6Sites

Recruiting5Sites

2024-12-30 - 2031-06-26

Phase III

Active
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

  • Condition/Disease

    Leukemia

  • Test Drug

    Film-coated tablets

Participate Sites
6Sites

Recruiting6Sites

2024-11-01 - 2029-12-31

Phase III

Active
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy

  • Condition/Disease

    Colorectal Neoplasms

  • Test Drug

    Injectable solution Injectable preparation Injectable preparation

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting4Sites

2025-03-01 - 2032-01-31

Phase III

Active
A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112/APGOT-OV13)

  • Condition/Disease

    Ovarian Cancer

  • Test Drug

    Frozen Crystal Injection

Participate Sites
7Sites

Recruiting7Sites

2024-12-30 - 2031-06-30

Phase II

Active
The RETIRE Trial: A Randomized Phase 2 Trial of Adoptive Therapy With Treg Adoptive Cell Transfer (TRACT) To Prevent Rejection in Living Donor Kidney Transplant Recipients

  • Condition/Disease

    Kidney Transplantation

  • Test Drug

    Suspension Injection

Participate Sites
4Sites

Recruiting4Sites

1 2 3 4 5 233
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB